XORTX Therapeutics Inc
XRTX
查看詳細走勢圖
0.560USD
-0.016-2.74%
收盤 12/24, 13:00（美東）報價延遲15分鐘
2.92M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-2.74%
5天
-4.22%
1月
-6.30%
6月
-30.14%
今年開始到現在
-50.40%
1年
-49.75%
查看詳細走勢圖
TradingKey XORTX Therapeutics Inc股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值合理，機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
XORTX Therapeutics Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
1
分析師
買入
評級
14.000
目標均價
+2058.50%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
XORTX Therapeutics Inc亮點
亮點風險
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
估值合理
公司最新PE估值-1.44，處於3年歷史合理位
機構減倉
最新機構持股63.97K股，環比減少90.99%
XORTX Therapeutics Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
XORTX Therapeutics Inc簡介
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
公司代碼XRTX
公司XORTX Therapeutics Inc
CEODavidoff (Allen W)
網址https://www.xortx.com/
常見問題
XORTX Therapeutics Inc(XRTX)的當前股價是多少？
XORTX Therapeutics Inc(XRTX)的當前股價是 0.560。
XORTX Therapeutics Inc 的股票代碼是什麼？
XORTX Therapeutics Inc的股票代碼是XRTX。
XORTX Therapeutics Inc股票的52週最高點是多少？
XORTX Therapeutics Inc股票的52週最高點是2.490。
XORTX Therapeutics Inc股票的52週最低點是多少？
XORTX Therapeutics Inc股票的52週最低點是0.700。
XORTX Therapeutics Inc的市值是多少？
XORTX Therapeutics Inc的市值是2.92M。
XORTX Therapeutics Inc的淨利潤是多少？
XORTX Therapeutics Inc的淨利潤為-3.31M。
現在XORTX Therapeutics Inc(XRTX)的股票是買入、持有還是賣出？
根據分析師評級，XORTX Therapeutics Inc(XRTX)的總體評級為買入，目標價格為14.000。
XORTX Therapeutics Inc(XRTX)股票的每股收益（EPS TTM）是多少
XORTX Therapeutics Inc(XRTX)股票的每股收益（EPS TTM）是-0.400。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
